Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triple-negative breast cancer
Biotech
Mersana lays off 55% of staff, narrows focus to B7-H4 ADC
The biotech is laying off 55% of its employees and cutting back internal R&D work to focus on lead program emiltatug ledadotin.
Nick Paul Taylor
May 6, 2025 9:40am
BioNTech posts overall survival data on would-be Keytruda killer
Dec 10, 2024 9:00am
Death drives Lyell to take 2-track approach to dose escalation
Jun 26, 2024 10:00am
Gilead draws up $20M pact with cancer biotech Cartography
May 28, 2024 10:26am
Puma pounces on failed Takeda drug, snapping up cancer prospect
Sep 21, 2022 9:05am
CytomX puts lead ADC on the block after phase 2 data underwhelm
Jul 7, 2022 8:45am
